Therapeutic use of mitochondria and combined mitochondrial agents

Abstract

The disclosure relates to compositions comprising isolated mitochondria or combined mitochondrial agents, and methods of treating disorders using such compositions.

1 .- 21 . (canceled) 
     
     
         22 . A method of delivering an agent to a target site of a subject, the method comprising administering to the subject a combined mitochondrial agent comprising mitochondria and the agent, to thereby deliver the agent to the target site of the subject. 
     
     
         23 . The method of  claim 22 , wherein the target site is heart, kidney, liver, pancreas, lung, gastrointestinal tract, eye, optic nerve, brain, or skeletal muscle of the subject. 
     
     
         24 . The method of  claim 22 , wherein the combined mitochondrial agent is administered into a blood vessel that carries blood to the target site. 
     
     
         25 . The method of  claim 22 , wherein the combined mitochondrial agent comprises the agent linked to mitochondria by a covalent bond. 
     
     
         26 . The method of  claim 22 , wherein the combined mitochondrial agent comprises the agent embedded in the mitochondrial membrane. 
     
     
         27 . The method of  claim 22 , wherein the agent is a therapeutic agent. 
     
     
         28 . The method of  claim 22 , wherein the agent is a diagnostic agent. 
     
     
         29 . The method of  claim 22 , wherein the combined mitochondrial agent further comprises an antibody or an antigen binding fragment. 
     
     
         30 .- 116 . (canceled) 
     
     
         117 . The method of  claim 22 , wherein the mitochondria are autogeneic to the subject. 
     
     
         118 . The method of  claim 117 , wherein the autogeneic mitochondria have exogenous mitochondrial DNA (mtDNA). 
     
     
         119 . The method of  claim 22 , wherein the mitochondria are allogeneic to the subject. 
     
     
         120 . The method of  claim 22 , wherein the mitochondria are xenogeneic to the subject. 
     
     
         121 . The method of  claim 22 , wherein the agent is  18 F-Rhodamine 6G. 
     
     
         122 . The method of  claim 22 , wherein the agent is iron oxide nanoparticle. 
     
     
         123 . The method of  claim 24 , wherein the blood vessel is the coronary artery of the subject or the greater pancreatic artery of the subject. 
     
     
         124 . The method of  claim 22 , wherein the combined mitochondrial agent does not cause an immune response. 
     
     
         125 . The method of  claim 27 , wherein the therapeutic agent is a cytotoxic agent. 
     
     
         126 . The method of  claim 125 , wherein the cytotoxic agent is a toxin. 
     
     
         127 . The method of  claim 125 , wherein the cytotoxic agent is a small molecule. 
     
     
         128 . The method of  claim 27 , wherein the therapeutic agent is a protein. 
     
     
         129 . The method of  claim 27 , wherein the therapeutic agent is a DNA. 
     
     
         130 . The method of  claim 27 , wherein the therapeutic agent is a RNA.